Patents Examined by M Franco G Salvoza
  • Vaccine composition for naive subjects
    Patent number: 11065325
    Abstract: The invention relates to nasally-administered vaccine compositions effective in naive subjects such as children. Further, the vaccine composition is suitable for vaccinating the general population during a pandemic. One aspect of the invention is directed to the paediatric use of the vaccine of the invention including a vaccine effective in children against seasonal influenza virus strains. A further aspect of the invention is directed to subjects of all age groups when the composition is for pandemic use.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: July 20, 2021
    Assignee: Eurocine Vaccines AB
    Inventors: Hans Arwidsson, Anna-Karin Maltais
  • Stabilisation method for viruses or bacteria
    Patent number: 11060068
    Abstract: The present invention relates to a method for stabilising viruses or bacteria, the method comprising embedding the viruses or bacteria in an aqueous solution, wherein the solution comprises: (i) at least three different amino acids; or (ii) at least one dipeptide or tripeptide and wherein the solution is free or substantially free of sugar(s), silanes and protein(s).
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: July 13, 2021
    Assignee: Leukocare AG
    Inventors: Martin Scholz, Jens Altrichter, Kristina Kemter
  • Stabilised FMDV capsids
    Patent number: 11053286
    Abstract: The present invention relates to the stabilisation of foot-and-mouth disease virus (FMDV) capsids, by specific substitution of amino acids in a specific region of FMDV VP2. The invention provides stabilised FMDV capsids and vaccines against FMD.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: July 6, 2021
    Assignee: The Pirbright Institute
    Inventors: Abhay Kotecha, David Stuart, Elizabeth Fry, Robert Esnouf
  • Human rhinovirus vaccine
    Patent number: 11040095
    Abstract: HRV VP2 proteins useful as components of immunogenic compositions for the induction of cross-reactive cell-mediated immunity against human rhinovirus infection; nucleic acid constructs encoding such HRV VP2 proteins.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: June 22, 2021
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Catherine Marie Ghislaine Gerard, Sandra Giannini, Julien Thierry Massaux
  • Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
    Patent number: 11041171
    Abstract: Adeno-associated virus rh.20 sequences, vectors containing same, and methods of use are provided.
    Type: Grant
    Filed: November 13, 2019
    Date of Patent: June 22, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira
  • Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
    Patent number: 11034976
    Abstract: Adeno-associated virus rh.10 sequences, vectors containing same, and methods of use are provided.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: June 15, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira
  • Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
    Patent number: 11034977
    Abstract: Adeno-associated virus rh.20 sequences, vectors containing same, and methods of use are provided.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: June 15, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira
  • Mutant of adeno-associated virus (AAV) capsid protein
    Patent number: 11028131
    Abstract: The present invention provides: a mutant of adeno-associated virus (AAV) capsid protein, which contains at least one amino acid substitution in PLA2 domain when compared with the amino acid sequence for wild-type AAV capsid protein; a nucleic acid encoding the mutant; a cell containing the nucleic acid; a method for producing a recombinant AAV particle, comprising a step of culturing the cell to produce the recombinant AAV particle; a recombinant AAV particle containing the mutant; a composition containing the recombinant AAV particle; and a method for transferring a gene into a target cell, comprising a step of bringing the recombinant AAV particle into contact with the target cell.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: June 8, 2021
    Assignees: NIPPON MEDICAL SCHOOL FOUNDATION, NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, TAKARA BIO INC.
    Inventors: Takashi Okada, Hironori Okada, Hiromi Kinoh, Tatsuji Enoki, Toshikazu Nishie, Junichi Mineno
  • Methods and compositions for the preparation of aerosols
    Patent number: 11007146
    Abstract: The present invention relates to methods for the preparation of an aerosol. More specifically the present invention provides methods for the preparation of an aerosol of immunoglobulin single variable domains wherein the amount of aggregate formation is significantly reduced. The invention further provides aerosols prepared by the methods of the invention, as well as compositions for use in the methods of the invention. The invention further relates to methods for the preparations of such compositions, to containers, kits and aerosol delivery systems comprising such compositions and to uses of the same.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: May 18, 2021
    Assignee: Ablynx N.V.
    Inventors: Erik Depla, Mauro Sergi, Peter Casteels
  • Adeno-associated virus purification methods
    Patent number: 11000561
    Abstract: Provided herein are methods of producing an adeno-associated virus (AAV) product, methods of purifying adeno-associated virus, and methods of purifying full AAV capsids from a concentrated AAV fraction comprising empty AAV capsids and full AAV capsids.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: May 11, 2021
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Christian Fiedler, Leopold Grillberger, Meinhard Hasslacher, Barbara Kraus, Dominik Mittergradnegger, Stefan Reuberger, Horst Schafhauser, Marian Bendik
  • Oncolytic adenovirus encoding a B7 protein
    Patent number: 11000559
    Abstract: The present disclosure provides a replication competent oncolytic adenovirus with selectivity for cancer cells, wherein the adenovirus comprises a transgene under the control of a promoter endogenous to the virus, wherein the transgene comprises a DNA sequence encoding a B7 protein or an active fragment thereof, compositions comprising same, methods of generating the viruses, and use of the viruses and compositions in treatment, particularly in the treatment of cancer.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: May 11, 2021
    Assignee: PsiOxus Therapeutics Limited
    Inventors: Brian Robert Champion, Alice Claire Noel Bromley
  • Immunity inducer
    Patent number: 10994007
    Abstract: Disclosed is an immunity inducer. The immunity inducer comprises virus like particles; the virus like particles comprise a virus-derived outer coat protein and an antigen-bound protein comprising an exogenous antigen; the outer coat protein constitutes an outer coat of the virus like particles, and the antigen-bound protein is comprised in the outer coat; and the virus like particles induce an immune effect of a living body on the antigen.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: May 4, 2021
    Assignees: Saitama Medical University, SYSMEX CORPORATION
    Inventors: Hiroshi Handa, Masaaki Kawano, Masahiko Kato
  • Composition for promoting production of immunostimulatory factor
    Patent number: 10987374
    Abstract: According to the present invention, various diseases, such as viral diseases, cancer, and multiple sclerosis, can be prevented and improved by using an immunostimulatory factor production-promoting composition comprising genomic double-stranded RNA of a plant-derived endornavirus.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: April 27, 2021
    Assignee: KYOTO UNIVERSITY
    Inventors: Takashi Fujita, Hiroki Kato, Tetsuya Nakazaki
  • Engineered and multimerized human immunodeficiency virus envelope glycoproteins and uses thereof
    Patent number: 10987417
    Abstract: Engineered and multimerized human immunodeficiency virus (HIV) envelope glycoproteins are described. The envelope glycoproteins can be multimerized using a heptamerization domain such as a C4b binding protein multimerization domain or a ferritin fusion. The engineered and multimerized envelope glycoproteins can derived from glycoprotein 120 (gp120) and can used as an HIV vaccine.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: April 27, 2021
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Roland K. Strong, Colin Correnti, Leonidas Stamatatos, Andrew McGuire
  • Retargeting of viruses or VLPs
    Patent number: 10975359
    Abstract: The present invention relates to a method of producing a polyomavirus or polyomavirus-derived virus-like particle (vlp) carrying on its surface at least one targeting molecule that binds to a cell of interest. Furthermore, the present invention relates to a composition comprising such a polyomavirus or polyomavirus-derived vlp and to the use of the polyomavirus or polyomavirus-derived vlp of the invention or the composition of the invention for use as a medicament. The present invention further relates to a kit comprising the polyomavirus or polyomavirus-derived vlp or the composition of the invention.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: April 13, 2021
    Assignee: Deutsches Primatenzentrum GmbH Leibniz-Institut für Primatenforschung
    Inventors: Jens Gruber, Stefan Schneider, Ellen Eckermann-Felkl, Alina Mosblech, Arnd Steuernagel, Dennis Wegener, Julian Plaga
  • Virus concentration method
    Patent number: 10969309
    Abstract: Provided is a method suitable for concentrating the viruses present in the environment, food or biomaterials in fields such as inspections for ensuring public or food safety and medical examinations, and reagents used therein. By adding an optimum concentration of polysaccharide such as glycogen to polyethylene glycol (PEG) and optimizing the concentration of a salt to be added, the viruses suspended in an aqueous solution can be easily, rapidly and stably recovered at a high recovery rate.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: April 6, 2021
    Assignee: KTEN BIO INC.
    Inventors: Naoyuki Nishimura, Hidetomo Samori
  • Method of treatment using oncolytic viruses
    Patent number: 10967015
    Abstract: A method for treating a tumor by administering to a subject in need of such treatment an effective amount for treating the tumor of a Poxviridae decapping deficient mutant virus. Also disclosed are mutant Poxviridae and pharmaceutical formulations for use in the method.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: April 6, 2021
    Assignee: New York University
    Inventor: Ian J Mohr
  • Adenoviral vector system for gene delivery
    Patent number: 10968464
    Abstract: Disclosed herein a unique cell line system to generate a novel bovine adenovirus vector that provides more gene insertion capabilities and better immunogenicity for inserted antigens. The unique cell line is used for generating and growing of the new adenovirus vectors for gene delivery or recombinant vaccine production.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: April 6, 2021
    Assignee: Purdue Research Foundation
    Inventor: Suresh Kumar Mittal
  • Antibody specifically binding to an isolated peptide derived from vimentin or a fragment binding to the peptide
    Patent number: 10961300
    Abstract: The present invention relates to an antibody specifically binding to the peptide of SEQ ID NO: 1, and specifically, to an antibody specifically binding to an isolated peptide of SEQ ID NO: 1 or a fragment binding to the peptide specifically binding to the peptide, a polynucleotide encoding the antibody or the fragment binding to the peptide, a vector containing the polynucleotide, a cell introduced with the vector, a method of producing the antibody or the fragment binding to the peptide using the cell, an antibody or a fragment binding to the peptide produced by the method, an antiviral composition containing the antibody or the fragment binding to the peptide, a composition for preventing or treating inflammatory diseases containing the antibody or the fragment binding to the peptide, and a method of treating infectious viral diseases or inflammatory diseases using the composition.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: March 30, 2021
    Assignee: IMMUNEMED INC.
    Inventors: Yoon Won Kim, Young Jin Kim, Hyo Jeong Hong, Sang Jin Park, Min Woo Kim, Sung Man Park
  • Compositions and kits for purification of viral particles from host cells
    Patent number: 10961512
    Abstract: The present disclosure provides methods for extracting viral particles from a sample comprising cells enclosing the viral particles. Also provided are kits that includes two or more items selected from a cell suspension solution, a cell lysis solution, a first fractionation solution, a second fractionation solution, a pellet suspension solution, a solid phase chromatography column, and a viral concentration set such as centrifugal filters.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: March 30, 2021
    Assignee: Dao-Yao He
    Inventor: Dao-Yao He